摘要
目的:探讨HE4在子宫内膜异位症患者血清中水平及其关系,寻找可以对疾病的发展进行监测较为准确而快捷的途径和方法。方法:分别采用ELISA法测定内异症患者(内异症组)和对照组1(盆腔良性包块)、对照组2(卵巢上皮癌)、对照组3(卵巢非上皮性恶性肿瘤组)的血清中HE4的浓度。结果:内异症组血清HE4的浓度60·38±10·26PM,与对照组1的浓度45·64±5·23PM相比,呈上升趋势,两组比较差异有统计学意义(P<0·05),与对照组2的浓度178·35±19·26PM相比,呈下降趋势,两组比较差异有统计学意义(P<0·05),与对照组3的浓度69·12±9·26PM相比,两组比较差异无统计学意义(P>0·05)。结论:内异症患者血清HE4与内异症的发生密切相关,HE4以50PM作为临界值可能会成为区分子宫内膜异位症与盆腔良性包块的重要依据。
Objective：To investigate the levels of HEd in serum of patients with endometriosis and their relationship with the disease and to find a quick and accurate method to dynamically monitor the development of endometriosis. Method ： Levels of HFA in serum were detected by radioimmunoassay and immunradionmentic assay in the patients with endometriosis and those without endometrosis. Result：In EMS group,the concentrations of HFA60. 38±10. 26 PM in serum were sl- gificantly higher than in the control group 1 [ HE4 （45.64±5.23 ） PM ]. And were sigificantly lower than in the control group 2 [HE4 （ 178. 35±19. 26） PM ]. And were similar to the control group 3 [ HE4（69.12±9.26 ） PM ]. Conclusions ： HE4 in serum in patients with endometriosis are closely related with pathegenesis of the disease. HE4 is useful for distinguishing those without endometrosis from endometriosis.
